All In Biotech

Drug Trial Radar · NCT02670161

Quality Improvement and Practice Based Research in Neurology Using the EMR

Quality Improvement and Practice Based Research in Neurology Using the Electronic Medical Record

Last checked: Nov 19, 2026Latest source record: Aug 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

3,300

Planned (sponsor's estimate)

Start

May 2016

Primary completion

Dec 2026

Study completion Dec 2027

Sponsor

Lead sponsor
Endeavor HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 1, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The investigators will conduct at NorthShore University HealthSystem pragmatic trials using the EMR for 10 common neurological disorders. They will demonstrate the feasibility of subgroup based adaptive assignment of treatments, electronic consenting, and outcomes data capture at the point of care using the EMR. They will identify the most effective treatments for common neurological disorders and seek replication by the NPBRN.

Conditions

  • Brain Tumors
  • Epilepsy
  • Migraine
  • Mild Cognitive Impairment
  • Concussion
  • Multiple Sclerosis
  • Neuropathy
  • Parkinson's
  • Restless Legs Syndrome
  • Stroke

Interventions

  • Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)Drug

    brain tumors (lamotrigine, levetiracetam, valproic acid), epilepsy (lamotrigine, levetiracetam, valproic acid), mild cognitive impairment (donepezil, rivastigmine, memantine), migraine (amitriptyline, propranolol, topiramate), migraine (sumatriptan, rizatriptan, zolmitriptan), mild traumatic brain injury (omega-3 fatty acids, education only), multiple sclerosis (ACTH, methylprednisolone), neuropathy (duloxetine, pregabalin, amitryptiline), Parkinson's disease (pramipexole, ropinerole, rotigotine), restless legs syndrome (pramipexole, ropinerole, rotigotine), stroke (aspirin, clopidogrel).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. survival free of discontinuation or alternative prevention drug (migraine trial)Time frame: six months
  2. survival free of disability measured by FAQ score 9+ (memory trial)Time frame: one year
  3. survival free of discontinuation or alternative anti epileptic drug (epilepsy trial)Time frame: one year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • NorthShore University HealthSystem

    Evanston, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.